News archive 2015
“Destination Therapy” has thus been definitively changed into “LVAD treatment”. New possibilities are emerging in hospitals where the supporting heart is already being implanted. People with certain forms of end-stage heart failure, who are not eligible for a ...
On October 7, 2015 it was announced that the acquisition of Thoratec by St. Jude Medical is a fact. On July 21, 2015, the news came that this acquisition ...
PLEASANTON, Calif., Oct. 7, 2015 / PRNewswire / - Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that all proposals necessary for…
There was some uncertainty as to whether the content of the press release, published on 11 March last, is a given or a recommendation. LVAD.nl has contacted the National Health Care Institute from where the…
The press release below was published on 11 March 2015: "A permanent support heart of the Left Ventricular Assist Device (LVAD) type can be part of the basic package for insured persons with heart failure.
Scientists have long been developing stem cells that could repair or replace a damaged or diseased heart. This turns out to be very difficult, especially because it ...
